Dr. Yair Levy's Guide to Targeted Therapy for Chronic Lymphocytic Leukemia

Dr. Yair Levy, a hematologist with Baylor University Medical Center in Dallas, explains what chronic lymphocytic leukemia (CLL) patients need to know about game-changing targeted treatments

Patients facing a chronic lymphocytic leukemia (CLL) diagnosis often encounter complex choices about their next steps in treatment, but targeted therapy developments have really changed the game.

Here, Dr. Yair Levy, hematologist, medical oncologist, and Director of Hematologic Malignancies Research at Texas Oncology–Baylor Charles A. Sammons Cancer Center, explains how targeted treatments, BTK inhibitors in particular, have changed how doctors approach treatment for CLL.

Your Digital Guide begins below: 2 Chapters / 4 Video Segments

×

Get SurvivorNet in Your Inbox

Our newsletter – vital information, hope, and healing, delivered weekly.

Never want to see this again? Click here to dismiss this module permanently.
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider